Paper Details

  1. Home
  2. Paper Details

Alpha interferon treatment in chronic hepatitis C.

Author: BellatiG, BellobuonoA, IdéoG, IdéoG M, MondazziL, SiliniE, TempiniS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Interferon treatment can improve liver function in at least half of people with chronic hepatitis C, but the condition often returns after treatment ends. Different interferon treatment schedules have been tried, but the best approach is still being debated. Different types of hepatitis C virus (HCV) have been identified, and the specific type of virus may affect how well interferon works.
Paper Details　
Original Abstract of the Article :
Alpha interferon (alpha IFN) treatment normalizes serum ALT levels in at least half of all patients affected by chronic hepatitis C, but a reactivation of the disease is frequently observed after the end of therapy. Different regimens of alpha IFN therapy have been proposed but the optimal schedule ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8730501

データ提供：米国国立医学図書館（NLM）

Alpha Interferon: A Treatment for Chronic Hepatitis C, But Not a Cure

The vast desert of liver disease research is constantly seeking new oases of hope for patients battling hepatitis C. This study explores the use of alpha interferon (IFN) in the treatment of chronic hepatitis C, a viral infection that can lead to severe liver damage. The authors review the effectiveness of alpha IFN in normalizing serum ALT levels, a marker of liver damage. The study highlights the challenges associated with alpha IFN treatment, including the frequent reactivation of the disease after therapy. The research also explores different regimens of alpha IFN therapy and the influence of HCV genotype on treatment response. The study's findings underscore the need for further research into more effective treatment strategies for chronic hepatitis C.

A Complex Terrain for Hepatitis C Treatment

This study provides a valuable overview of the use of alpha interferon in treating chronic hepatitis C. The research highlights the challenges associated with this treatment, including the frequent reactivation of the disease after therapy. This study underscores the need for ongoing research into more effective and long-lasting treatment options for chronic hepatitis C, offering hope for a brighter future for patients facing this challenging disease.

Navigating the Desert of Liver Disease

This study emphasizes the importance of continued research into the treatment of chronic hepatitis C. The research highlights the need to develop more effective and long-lasting therapies that can effectively suppress the virus and prevent the development of severe liver damage. Just as a camel must navigate the treacherous terrain of the desert, we must continue to explore new pathways and solutions to conquer this formidable disease.

Dr. Camel's Conclusion

This study offers valuable insights into the use of alpha interferon in treating chronic hepatitis C. The research highlights the need for continued research to develop more effective and long-lasting treatment options that can effectively suppress the virus and prevent the development of severe liver damage. Like a determined camel traversing the vast desert, we must continue to seek new oases of hope in our quest to conquer this challenging disease.

Date :
  1. Date Completed 1996-10-02
  2. Date Revised 2017-01-12
Further Info :

Pubmed ID

8730501

DOI: Digital Object Identifier

8730501

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.